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The mammalian target of rapamycin 
(mTOR) is a major regulator of cell 
growth, motility and angiogenesis that 
is often deregulated in malignancies. 
mTOR inhibitors have been approved for 
the treatment of renal cell carcinoma and 
mantle cell lymphoma. Currently, second-
generation mTOR inhibitors are under 
clinical evaluation.1 Major challenges 
remain in the identification of patients 
who will respond to mTOR inhibitors and 
the development of therapeutics that can 
overcome intrinsic resistance or acquired 
resistance. There are currently no bio-
markers that predict tumor response to 
mTOR inhibitors.
MicroRNAs (miRNAs) are endog-
enous small non-coding RNAs that regu-
late gene expression. MiRNAs participate 
in many biological processes, including 
proliferation and apoptosis. MiRNAs 
are often deregulated in cancer and act 
as tumor suppressors or oncogenes.2 
Recently miRNAs emerged as diagnostic 
and prognostic markers to assess thera-
peutic responses, giving rise to the field of 
miRNA pharmacogenomics.3 Numerous 
studies indicate that mTOR and its sig-
naling pathway is regulated by miRNAs. 
However, little is known as to whether 
miRNAs play a role in the intrinsic tumor 
resistance or the development of acquired 
resistance to mTOR inhibitors.
In our recent studies we used rapamy-
cin-resistant (RR1) variants of the murine 
brain tumor cell line BC3H1, developed 
by chronic rapamycin treatment. We 
previously showed that these RR1 cells 
exhibit persistent hyperphosphorylation 
of retinoblastoma protein, releasing the 
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transcription factor E2F to increase the 
expression of Skp2 (substrate recognition 
subunit of the SCFSKP2 ubiquitin ligase 
complex), which, in turn, increases the 
turnover of the cyclin-dependent kinase 
inhibitor p27.4,5 We also showed that in 
both RR1 cells and the parental rapamy-
cin-sensitive BC3H1 cells, rapamycin 
inhibited mTORC1 and mTORC2 in 
the same manner, suggesting that RR1 
cells have developed an mTOR-inde-
pendent mechanism to survive (Fig. 1).6 
Intriguingly, RR1 cells exhibited extensive 
reprogramming of miRNA expression, 
characterized by upregulation of onco-
genic miR-17-92 clusters and downregu-
lation of tumor suppressors miRNAs. In 
contrast, rapamycin-sensitive cells exhib-
ited an increase in tumor suppressor miR-
NAs.6 The dysregulated miRNAs found 
in RR1 cells affected global gene expres-
sion and were associated with an increase 
in the expression of the oncogene Myc 
(Fig. 1). Downregulation of Myc or inhi-
bition of miR-19 or miR-17, which share 
seed sequences with other members of the 
miR-17-92 cluster, restored the sensitiv-
ity of RR1 cells to rapamycin, suggesting 
that the miR-17-92 cluster may mediate 
Myc-induced resistance to rapamycin. We 
also showed that RR1 cells have adopted 
a miRNA-based homeostatic mechanism 
to resist tumor-suppression networks such 
as TGFβ (Fig. 1).
Figure 1. MicrorNas affect the cellular response to rapamycin. in rapamycin-resistant cells, both 
mtorC1 and mtorC2 were inhibited by rapamycin and also exhibited upregulation of Myc and 
the oncogenic mir-17-92 and related clusters (in red) and downregulation of tumor suppressors 
mirNas (in black). upregulation of let-7 or downregulation of mir-19 or mir-17, members of mir-
17-92 cluster, restored sensitivity to rapamycin.
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Myc upregulates the oncogenic miR-17-
92 clusters and miR-19, a key component 
of these clusters promoted cell survival 
by targeting PTEN.7 On the other hand, 
Myc also downregulates numerous tumor-
suppressor miRNAs, including the let-7 
family of miRNA, which suppresses its 
own expression. In fact, we showed that 
the let-7 family of miRNAs antagonizes 
the expression of Myc and mediates the 
inhibitory effect of rapamycin.
This work has numerous implications 
for cancer therapies. It shows that miR-
NAs may affect the cellular responses to 
rapamycin and therefore can be used as 
biomarkers to assess the efficacy of mTOR-
targeted therapy. Moreover, these recent 
studies may lead to the development of 
novel miRNA-based targeted therapy to 
treat rapamycin-resistant tumors.
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